Longino & Cardenal SPA (LON) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Longino & Cardenal SPA stock €0.59, price €1.34, that is 56.0% below the price, quality 55 out of 100. Rating: strongly overvalued. Calculated from audited financials with 11 of our 26 valuation models and 37 quality factors, updated daily.
Longino & Cardenal S.p.A., together with its subsidiaries, provides catering services to the hotel, restaurant, catering, and gastronomy sectors in Italy, rest of the European Union, and internationally.
Show moreShow less
It distributes food products through its online platform comprising caviar; fish products and specialties, such as oysters, mollusks, bivalves, canned fish, crustaceans, fish, and marine planktons; meats and cured meat products, including cattle, pigs, sheep, goats, farmyard animals, foie gras, and furred and feathered game birds; and Italian cheeses, butter, French cheeses, yogurt, and eggs.
The company also offers fruits and vegetables, flowers, buds, aromatic herbs, garlic and black shallots, fruit and vegetable preserves, truffles, mushrooms, juices, and vegetable sheets; bread, breadsticks, pasta, rice, legumes, and flours; salt, spices, oil, vinegar, sauces, condiments, and molecular cuisine; and chocolates, pralines, cream and dessert products, nougats, and fruits and candied fruits.
Longino & Cardenal S.p.A. was founded in 1988 and is based in Pogliano Milanese, Italy.
Stock analysis
Longino & Cardenal SPA (LON) currently trades at €1.34, while our model-based Fair Value estimate is €0.5900, 56% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of €1.97 per share, and 5 of the 11 models we run sit above the €1.34 price.
Bear case: the Earnings-Based group reads lowest at €0.0700, and 6 of the 11 models stay below the price. Data coverage for this calculation is medium.
Scenario range: €0.2400 (bear) to €0.9300 (bull), the price of €1.34 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Consumer Defensive sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Longino & Cardenal SPA reported revenue of €35.3M in FY2025 versus €26.9M in FY2021, a compound +7.0%/yr. Reported net income was −€653K in FY2025.
Key figures
Market cap €8.4M Micro · P/E ratio 11.2 · P/S ratio 0.24 · EPS (TTM) €0.1200 · Net margin 2.1% · Return on equity 28.6% · Return on assets (EBIT) −2.2% (5-year average) · Operating margin 1.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 6% below its 52-week high and 79% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −10% fair-value upside, at −56%, LON screens richer than that median.
Fair Value models
Bear€0.2400Fair Value €0.5900Bull€0.9300
Price €1.34 · Downside -56.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (€0.1029 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.71/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−6.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.3%
Start year 2020 (pandemic). Over 10 years: +7.1% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.1%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−7.0% (2020) → 0.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+2.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+2.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +0.1% a year for the price and +0.7% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Food Distribution · 85 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score55 · Above median
Fair Value upside−56.0% · Bottom 25%
Profitability
Return on equity (12 months)28.6% · Top 25%
Return on assets−3.9% · Bottom 25%
Net margin (12 months)2.1% · Above median
Operating margin (12 months)1.7% · Below median
Growth and dividend
Revenue growth (quarter YoY)−7.9% · Bottom 25%
Balance sheet
Debt / equity0.93× · Highest 25%
Valuation Multiplesvs Food Distribution median · lower = cheaper
P/E (12 months)11.2× · Cheaper than median
P/B2.91× · Priciest 25%
P/S (12 months)0.24× · Cheaper than median
Price / free cash flow (fiscal year)7.7× · Cheaper than median
EV/EBITDA5.2× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 37
FUTURE (revenue growth)0· sector 9
PAST (return on equity)100· sector 31
HEALTH (low debt)54· sector 93
DIVIDEND (yield)0· sector 61
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Longino & Cardenal SPA (LON) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of €0.5900 versus a price of €1.34, about 56% lower (overvalued).
What is the fair value of LON?
Our model-based fair value for Longino & Cardenal SPA is €0.5900 (as of Nov 4, 2026), built from audited fundamentals. The current price: €1.34.
What is the quality score of LON?
Longino & Cardenal SPA has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Longino & Cardenal SPA (LON)?
Our model-based price target is the fair value of €0.5900 (as of Nov 4, 2026) from 11 valuation models. Cautious scenario €0.2400, optimistic scenario €0.9300. It is a calculation from audited fundamentals, not an analyst target.
What is the Longino & Cardenal SPA stock forecast for 2026?
Our models put fair value at €0.5900, about 56% lower versus a price of €1.34 (overvalued). Cautious scenario €0.2400, optimistic scenario €0.9300. The calculation is refreshed regularly with new filings.
What is the revenue of Longino & Cardenal SPA (LON)?
Longino & Cardenal SPA reported trailing-twelve-month revenue of about €34.6M (latest available figure, as of Nov 4, 2026).
What growth is priced into Longino & Cardenal SPA (LON)?
For today's price to be fair in a discounted-cash-flow model, Longino & Cardenal SPA would have to grow free cash flow by +2.3 % per year for five years (discount rate 10.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.3 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of LON use?
Our models discount Longino & Cardenal SPA at 10.5 %: a base by market capitalisation (nano), damped by beta 0.21, country premium for Italy. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Longino & Cardenal SPA that is +2.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.5 %) and the same formula as our fair value.
How much growth has Longino & Cardenal SPA (LON) delivered so far?
Over the past 5 years revenue at Longino & Cardenal SPA grew +12.3 % a year. The price currently implies free-cash-flow growth of +2.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Longino & Cardenal SPA (LON) growing?
The median revenue growth in the sector is +3.6 % a year. That is the yardstick for the growth priced into Longino & Cardenal SPA (+2.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Longino & Cardenal SPA (LON)?
The free-cash-flow yield on the price is 12.93 %: that much free cash flow Longino & Cardenal SPA produces per unit of market value. When it exceeds the discount rate of our models (10.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Longino & Cardenal SPA (LON)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Longino & Cardenal SPA it is €0.5900 per share (as of Nov 4, 2026), against a price of €1.34. It is the blended result of 11 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit).
Is Longino & Cardenal SPA stock overvalued or undervalued in 2026?
As of Nov 4, 2026, LON trades above its calculated fair value: price €1.34, fair value €0.5900, a gap of about −56% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LON?
No. The price is what the market pays today (€1.34); the fair value is what the company's own numbers justify (€0.5900). For Longino & Cardenal SPA the two are €0.7500 per share apart. That gap is exactly why we show both numbers side by side.
How much is Longino & Cardenal SPA worth?
The market values Longino & Cardenal SPA at about €8.4M (market capitalisation, as of Nov 4, 2026). Per share that is €1.34; our models calculate a fair value of €0.5900 per share.
What do the bullish and bearish scenarios say about LON?
Our models span a range for Longino & Cardenal SPA: cautious scenario €0.2400, base €0.5900, optimistic €0.9300 per share (as of Nov 4, 2026, price €1.34). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of LON?
Longino & Cardenal SPA trades at a price-to-earnings ratio of 11.2 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €0.5900 is built from several models across several years. Other multiples: P/B 2.9, P/S 0.2, EV/EBITDA 5.2.
How solid is the balance sheet of Longino & Cardenal SPA (LON)?
Balance-sheet figures for Longino & Cardenal SPA (as of Nov 4, 2026): return on equity 28.6%, debt of 0.93 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is LON from its 52-week high?
Longino & Cardenal SPA trades at €1.34, about 6% below its 52-week high of €1.42 and 79% above the low of €0.7500 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of €0.5900 is for.
Which stocks are comparable to Longino & Cardenal SPA?
From the same area (Consumer Defensive) we also value Sysco Corporation, US Foods Holding, Performance Food Group, Jerónimo Martins, SGPS, S.A, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Longino & Cardenal SPA stock attractive at the current price?
The data as of Nov 4, 2026: price €1.34, calculated fair value €0.5900 (−56%), Quality Score 55/100, from 11 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LON calculated?
We run Longino & Cardenal SPA through 11 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of €0.5900 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Longino & Cardenal SPA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Longino & Cardenal SPA (LON)?
The closing price on Nov 6, 2026 was €1.34. Our model-based fair value is €0.5900, about 56% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Longino & Cardenal SPA right now?
The price sits above even our optimistic bull case (€0.9300). The favourable scenario is already priced in. The model range is unusually wide (€0.2400 to €0.9300). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Longino & Cardenal SPA
How large is the market capitalisation of Longino & Cardenal SPA (LON)?
The market capitalisation of Longino & Cardenal SPA is €8.4M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Longino & Cardenal SPA (LON)?
The price-to-sales ratio of Longino & Cardenal SPA is 0.24 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Longino & Cardenal SPA (LON)?
Earnings per share at Longino & Cardenal SPA are €0.1200 (price ÷ EPS = P/E 11.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Longino & Cardenal SPA (LON)?
The net margin of Longino & Cardenal SPA is 2.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Longino & Cardenal SPA (LON)?
The return on equity (ROE) of Longino & Cardenal SPA is 28.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Longino & Cardenal SPA (LON)?
On an EBIT basis the return on assets of Longino & Cardenal SPA is −2.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Longino & Cardenal SPA (LON)?
The operating margin of Longino & Cardenal SPA is 1.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Longino & Cardenal SPA (LON)?
Revenue at Longino & Cardenal SPA is growing −7.9% versus a year earlier (3y avg +3.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Longino & Cardenal SPA (LON)?
Earnings per share at Longino & Cardenal SPA are growing −31.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Longino & Cardenal SPA (LON) carry?
The net debt of Longino & Cardenal SPA is €4.9M (fiscal year 2025, ≈ 4.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Longino & Cardenal SPA in the live analysis
One click puts Longino & Cardenal SPA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 4, 2026